

**Supplementary Table 1: Treatment Groups**

		Test Material	Dose	Route & Frequency	Study Duration post Last Dosing Session	
					3 Days Main Phase (Day 31)	3 weeks Recovery Phase (Day 49)
Treatment groups	<i>n=20</i> (10♂ & 10♀)	Vehicle Control	0	3 Repeated IM injections at an interval of 2 weeks (Days 0, 14 & 28)	<i>n=10</i> (5♂ & 5♀)	<i>n=10</i> (5♂ & 5♀)
	<i>n=20</i> (10♂ & 10♀)	Vaccine Low Dose	1×10 <sup>6</sup> PFU/ml		<i>n=10</i> (5♂ & 5♀)	<i>n=10</i> (5♂ & 5♀)
	<i>n=20</i> (10♂ & 10♀)	Vaccine High Dose	1×10 <sup>7</sup> PFU/ml		<i>n=10</i> (5♂ & 5♀)	<i>n=10</i> (5♂ & 5♀)

**Supplementary Table 2: Study outline and endpoints**

<p><b>In-Life Examination:</b></p>		<p><b>Clinical examination:</b> morbidity and mortality (twice daily), clinical signs (once daily) detailed clinical examination (once weekly)  <b>Local Reaction (Draize scoring):</b> 4-6 hours post dosing, 1 day post each dosing session and once weekly thereafter  <b>Body Temperature:</b> at acclimation, 4-6 hours &amp; 1 day post each dosing session (in case an increase in body temperature were noted, additional measurements were carried)  <b>Body Weight:</b> at acclimation, prior to each dosing session, 3 days post dosing and thereafter once weekly.  <b>Food Consumption:</b> at acclimation, at dosing day, 3 days post dosing and thereafter once weekly. once weekly.  <b>Ophthalmic Examinations:</b> at acclimation and prior to each scheduled sacrifice session.</p> <p><b>Blood Collection:</b></p> <ul style="list-style-type: none"> <li>• CRP – Determined prior to the first dosing session on day -1 (baseline) &amp; 3 and 7 days post each dosing session (i.e. Days 17, 21, 31 &amp; 35) in 5 males &amp; 5 females per group.</li> <li>• Immunogenicity – Determined on days -1 (baseline) &amp; 13, 27 (i.e. a day prior to the 2nd and 3rd dosing session) and 49 in 5 males &amp; 5 females per group.</li> <li>• Viremia – Determined on days 2 &amp; 7 and prior to each scheduled termination time point (Days 31 and 49) in 5 males &amp; 5 females per group.</li> <li>• Hematology, Biochemistry and Coagulation Parameters: Determined at baseline, Day 3 and prior to each scheduled termination time point (Days 31 and 49) .</li> </ul> <p><b>Urine Collection:</b></p> <ul style="list-style-type: none"> <li>• Urinalysis: Prior to each scheduled termination time point (Days 31 and 49) .</li> <li>• Viruria –Days 2 &amp; 7 and prior to each scheduled termination time point (Days 31 and 49) in 5 males &amp; 5 females per group.</li> </ul>
<p><b>Necropsy:</b></p>		<p><b>Gross Pathology:</b> Full detailed macroscopic examination at each scheduled termination time point (Days 31 and 49)  <b>Organ Weight:</b> Adrenals, Brain, Epididymides, Heart, Kidneys, Liver, Lungs, Ovaries, Pituitary, Spleen, Testes, Thymus, Thyroid and Uterus &amp; cervix.</p>
<p><b>Biodistribution:</b></p>		<p>Samples from the following tissues/organs was collected: Brain, Ovary/Testes, Liver, Thymus, Heart, Lung, Kidney, Spleen, Mesenteric lymph node, Iliac lymph node, Subcutaneous tissue at the injection site, Thigh muscle at the injection site (3 injection sites), Bone marrow (from femur)</p>
<p><b>Histopathology:</b></p>		<p>Full histopathological examinations from the Main Phase animals (n=30 rabbits) was carried out by a board-certified pathologist.</p>

**Supplementary Table 3: Mean Temperature Values**

Dose level (Sex)		Temperature (°C) (Pre-Dosing)													
		Acclimation 1	Acclimation 2	0	1	2	3	14	15	16	17	28 <sup>17</sup>	29	30	31
<b>0 - Control (Females)</b>	<b>Mean</b>	39.30	39.09	39.23	39.16	39.07	38.96	40.18	39.18	39.27	39.17	39.45	39.29	39.24	39.29
	<b>SD</b>	0.114	0.219	0.248	0.165	0.257	0.087	0.703	0.156	0.112	0.138	0.140	0.131	0.175	0.102
	<b>n</b>	10	10	10	10	10	10	10	10	10	10	10	10	10	10
<b>10<sup>6</sup> Pfu/ml (Females)</b>	<b>Mean</b>	39.40	39.11	39.52**↑	39.25	39.13	38.99	40.37	39.26	39.19	39.24	39.52	39.38	39.39	39.30
	<b>SD</b>	0.260	0.127	0.193	0.175	0.322	0.267	0.591	0.254	0.207	0.120	0.231	0.174	0.200	0.223
	<b>n</b>	10	10	10	10	10	10	10	10	10	10	10	10	10	10
<b>10<sup>7</sup> Pfu/ml (Females)</b>	<b>Mean</b>	39.34	39.25	39.52**↑	39.28	39.19	38.93	40.03	39.34	39.24	39.18	39.46	39.32	39.30	39.28
	<b>SD</b>	0.287	0.145	0.184	0.160	0.366	0.226	0.670	0.194	0.127	0.119	0.174	0.098	0.134	0.128
	<b>n</b>	10	10	10	10	10	10	10	10	10	10	10	10	10	10
<b>0 - Control (Males)</b>	<b>Mean</b>	39.11	39.24	39.24	38.87	39.12	38.77	40.14	39.19	39.16	39.20	39.28	39.27	39.23	39.10
	<b>SD</b>	0.177	0.241	0.203	0.167	0.230	0.134	0.567	0.170	0.186	0.260	0.248	0.137	0.088	0.122
	<b>n</b>	10	10	10	10	10	10	10	10	10	10	10	10	10	10
<b>10<sup>6</sup> Pfu/ml (Males)</b>	<b>Mean</b>	39.09	39.21	39.30	39.06*↑	39.09	38.94	39.84	39.18	39.12	39.11	39.40	39.33	39.16	39.00
	<b>SD</b>	0.264	0.163	0.180	0.142	0.175	0.121	0.647	0.150	0.198	0.139	0.317	0.081	0.125	0.143
	<b>n</b>	10	10	10	10	10	10	10	10	10	10	10	10	10	10
<b>10<sup>6</sup> Pfu/ml (Males)</b>	<b>Mean</b>	38.91	39.27	39.32	38.98	39.11	38.90	39.71	39.13	39.19	39.04	39.36	39.29	39.17	39.06
	<b>SD</b>	0.172	0.178	0.164	0.196	0.131	0.241	0.639	0.107	0.247	0.316	0.276	0.120	0.183	0.087
	<b>n</b>	10	10	10	10	10	10	10	10	10	10	10	10	10	10

\*p<0.05 Vs. Control, \*\* p<0.01 Vs. Control; (multiple comparisons test); ↓: Decrease ↑: Increase

**Supplementary Table 4: Biodistribution of rVSV-ΔG-SARS-CoV-2-S Vaccine**  
qPCR Ct values and calculated Vaccine amounts (PFU) in each tissue sample

<b>Lung</b>		N (Ct - Av.)	N (Ct - STD)	S (Ct - Av.)	S (Ct - STD)	HPRT (Ct - Av.)	HPRT (Ct - STD)	<b>Vaccine amount (PFU) - N</b>	<b>Vaccine amount (PFU) - S</b>
#	Sample								
<b>1M - Control main</b>									
<b>1</b>	<b>3447 4.1</b>	36.51	0.01	41.84	0.71	26.15	0.37	<b>NA</b>	<b>NA</b>
<b>2</b>	<b>3473 4.1</b>	37.61	0.81	ND	NA	27.37	0.21	<b>NA</b>	<b>NA</b>
<b>3</b>	<b>3511 4.1</b>	ND	NA	41.02	0.81	27.88	0.47	<b>NA</b>	<b>NA</b>
<b>1F - Control main</b>									
<b>4</b>	<b>3470 4.1</b>	36.74	0.03	ND	NA	26.76	0.10	<b>NA</b>	<b>NA</b>
<b>5</b>	<b>3395 4.1</b>	37.23	0.22	ND	NA	26.83	0.44	<b>NA</b>	<b>NA</b>
<b>6</b>	<b>3489 4.1</b>	ND	NA	ND	NA	26.90	0.37	<b>NA</b>	<b>NA</b>
<b>3M - High dose main</b>									
<b>7*</b>	<b>3485 4.1</b>	ND	NA	ND	NA	ND	NA	<b>NA</b>	<b>NA</b>
<b>8</b>	<b>3486 4.1</b>	36.62	1.23	ND	NA	27.88	0.35	<b>NA</b>	<b>NA</b>
<b>9</b>	<b>3531 4.1</b>	36.875	0.05	ND	NA	29.89	1.87	<b>NA</b>	<b>NA</b>
<b>3F - High dose main</b>									
<b>10</b>	<b>3483 4.1</b>	36.905	2.65	41.33	1.62	27.06	0.66	<b>NA</b>	<b>NA</b>
<b>11</b>	<b>3490 4.1</b>	ND	NA	ND	NA	28.80	1.47	<b>NA</b>	<b>NA</b>
<b>12</b>	<b>3379 4.1</b>	36.675	0.45	ND	NA	26.70	0.47	<b>NA</b>	<b>NA</b>

Skin & subcutaneous tissue		N (Ct - Av.)	N (Ct - STD)	S (Ct - Av.)	S (Ct - STD)	HPRT (Ct - Av.)	HPRT (Ct - STD)	Vaccine amount (PFU) - N	Vaccine amount (PFU) - S
#	Sample								
<b>1M - Control main</b>									
14	3447 11.1	ND	NA	40.82	1.01	28.33	0.06	NA	NA
13	3473 11.1	ND	NA	42.16	0.68	27.42	0.19	NA	NA
15	3511 11.1	ND	NA	41.08	0.65	29.06	0.23	NA	NA
<b>1F - Control main</b>									
16	3470 11.1	ND	NA	ND	NA	24.97	0.23	NA	NA
17	3395 11.1	37.91	1.27	ND	NA	28.19	0.13	NA	NA
18	3489 11.1	36.65	0.93	ND	NA	25.19	0.01	NA	NA
<b>3M - High dose main</b>									
19	3485 11.1	ND	NA	ND	NA	27.27	0.08	NA	NA
20	3486 11.1	ND	NA	ND	NA	26.73	0.32	NA	NA
21**	3531 11.1	ND	NA	ND	NA	ND	NA	NA	NA
<b>3F - High dose main</b>									
22	3483 11.1	ND	NA	ND	NA	27.65	0.35	NA	NA
23	3490 11.1	ND	NA	ND	NA	29.72	0.21	NA	NA
24	3379 11.1	37.22	1.41	41.1	0	29.61	0.45	NA	NA

<b>Colon</b>		<b>N (Ct - Av.)</b>	<b>N (Ct - STD)</b>	<b>S (Ct - Av.)</b>	<b>S (Ct - STD)</b>	<b>HPRT (Ct - Av.)</b>	<b>HPRT (Ct - STD)</b>	<b>Vaccine amount (PFU) - N</b>	<b>Vaccine amount (PFU) - S</b>
<b>#</b>	<b>Sample</b>								
1M - Control main									
<b>35</b>	<b>3447.13.1</b>	ND	NA	ND	NA	26.22	0.06	<b>NA</b>	<b>NA</b>
<b>34</b>	<b>3473.13.1</b>	ND	NA	ND	NA	31.54	0.20	<b>NA</b>	<b>NA</b>
<b>36</b>	<b>3511.13.1</b>	37.11	0.06	ND	NA	25.52	0.15	<b>NA</b>	<b>NA</b>
1F - Control main									
<b>28</b>	<b>3470.13.1</b>	36.3	0.40	ND	NA	26.17	0.18	<b>NA</b>	<b>NA</b>
<b>25</b>	<b>3395.13.1</b>	ND	NA	ND	NA	30.84	0.33	<b>NA</b>	<b>NA</b>
<b>26</b>	<b>3489.13.1</b>	ND	NA	ND	NA	26.47	0.13	<b>NA</b>	<b>NA</b>
3M - High dose main									
<b>32</b>	<b>3485.13.1</b>	ND	NA	ND	NA	27.18	0.14	<b>NA</b>	<b>NA</b>
<b>30</b>	<b>3486.13.1</b>	ND	NA	40.98	1.54	27.13	0.16	<b>NA</b>	<b>NA</b>
<b>29</b>	<b>3531.13.1</b>	36.95	0.11	ND	NA	26.03	0.11	<b>NA</b>	<b>NA</b>
3F - High dose main									
<b>33</b>	<b>3483.13.1</b>	ND	NA	ND	NA	27.37	0.62	<b>NA</b>	<b>NA</b>
<b>27</b>	<b>3490.13.1</b>	ND	NA	40.79	0.78	26.39	0.05	<b>NA</b>	<b>NA</b>
<b>31</b>	<b>3379.13.1</b>	ND	NA	ND	NA	27.47	0.26	<b>NA</b>	<b>NA</b>



2	3447 14.1.2.1	36.86	0.63	ND	NA	27.87	0.08	NA	NA
5	3473 14.1.2.1	ND	NA	ND	NA	27.71	0.15	NA	NA
8***	3511 14.1.2.1	34.93	1.00	40.29	0.06	25.99	0.16	<10	NA
<b>1F - Control main</b>									
11	3470 14.1.2.1	ND	NA	ND	NA	28.66	0.06	NA	NA
14	3395 14.1.2.1	ND	NA	ND	NA	27.85	0.22	NA	NA
17	3489 14.1.2.1	ND	NA	ND	NA	28.11	0.20	NA	NA
<b>3M - High dose main</b>									
20	3485 14.1.2.1	ND	NA	ND	NA	27.81	0.37	NA	NA
23	3486 14.1.2.1	36.37	0.55	ND	NA	28.45	0.05	NA	NA
26	3531 14.1.2.1	ND	NA	ND	NA	29.94	0.35	NA	NA
<b>3F - High dose main</b>									
29	3483 14.1.2.1	ND	NA	ND	NA	30.90	0.03	NA	NA
32	3490 14.1.2.1	ND	NA	ND	NA	30.00	0.25	NA	NA
35	3379 14.1.2.1	35.15	0.10	41.14	0.71	26.10	0.08	<10	NA



Thigh muscle 3 pieces - P,M,D		N (Ct - Av.)	N (Ct - STD)	S (Ct - Av.)	S (Ct - STD)	HPRT (Ct - Av.)	HPRT (Ct - STD)	Vaccine amount (PFU) - N	Vaccine amount (PFU) - S
#	Sample								
1M - Control main									
3	3447 14.1.3.1	ND	NA	ND	NA	27.82	0.21	NA	NA
6	3473 14.1.3.1	35.46	0.49	ND	NA	26.32	0.40	<10	NA
9	3511 14.1.3.1	ND	NA	ND	NA	26.44	0.13	NA	NA
1F - Control main									
12	3470 14.1.3.1	35.56	0.49	ND	NA	25.94	0.07	<10	NA
15	3395 14.1.3.1	ND	NA	ND	NA	28.32	0.01	NA	NA
18	3489 14.1.3.1	ND	NA	ND	NA	27.57	0.19	NA	NA
3M - High dose main									
21	3485 14.1.3.1	36.17	0.06	ND	NA	28.97	0.36	NA	NA
24	3486 14.1.3.1	ND	NA	ND	NA	28.12	0.04	NA	NA
27	3531 14.1.3.1	34.07	0.06	40.09	1.06	29.29	0.08	25.90	NA
3F - High dose main									
30	3483 14.1.2.1	ND	NA	ND	NA	30.16	0.21	NA	NA
33	3490 14.1.3.1	ND	NA	ND	NA	30.06	0.58	NA	NA
36	3379 14.1.3.1	ND	NA	ND	NA	27.90	0.07	NA	NA

<b>Spleen</b>		N (Ct - Av.)	N (Ct - STD)	S (Ct - Av.)	S (Ct - STD)	HPRT (Ct - Av.)	HPRT (Ct - STD)	Vaccine amount (PFU) - N	Vaccine amount (PFU) - S
#	Sample								
<b>1M - Control main</b>									
<b>2</b>	<b>3447 5.1</b>	ND	NA	ND	NA	26.89	0.22	NA	NA
<b>6</b>	<b>3473 5.1</b>	ND	NA	ND	NA	23.45	0.00	NA	NA
<b>10</b>	<b>3511 5.1</b>	ND	NA	ND	NA	28.03	0.23	NA	NA
<b>1F - Control main</b>									
<b>21</b>	<b>3470 5.1</b>	ND	NA	ND	NA	30.11	0.12	NA	NA
<b>24</b>	<b>3395 5.1</b>	ND	NA	ND	NA	26.75	0.54	NA	NA
<b>17</b>	<b>3489 5.1</b>	ND	NA	ND	NA	27.18	0.02	NA	NA
<b>3M - High dose main</b>									
<b>19</b>	<b>3485 5.1</b>	ND	NA	ND	NA	27.83	0.10	NA	NA
<b>13</b>	<b>3486 5.1</b>	ND	NA	ND	NA	28.49	0.13	NA	NA
<b>15</b>	<b>3531 5.1</b>	ND	NA	ND	NA	27.65	0.21	NA	NA
<b>3F - High dose main</b>									
<b>36</b>	<b>3483 5.1</b>	ND	NA	ND	NA	27.40	0.46	NA	NA
<b>35</b>	<b>3490 5.1</b>	ND	NA	ND	NA	29.25	0.05	NA	NA
<b>34</b>	<b>3379 5.1</b>	ND	NA	ND	NA	27.03	0.27	NA	NA

Mesenteric lymph node		N (Ct - Av.)	N (Ct - STD)	S (Ct - Av.)	S (Ct - STD)	HPRT (Ct - Av.)	HPRT (Ct - STD)	Vaccine amount (PFU) - N	Vaccine amount (PFU) - S
#	Sample								
<b>1M - Control main</b>									
3	3447 7.1	ND	NA	ND	NA	25.89	0.04	NA	NA
7	3473 7.1	ND	NA	ND	NA	29.96	0.01	NA	NA
11	3511 7.1	ND	NA	ND	NA	24.17	0.12	NA	NA
<b>1F - Control main</b>									
22	3470 7.1	ND	NA	ND	NA	26.33	0.08	NA	NA
23	3395 7.1	ND	NA	ND	NA	26.52	0.01	NA	NA
18	3489 7.1	ND	NA	ND	NA	27.02	0.13	NA	NA
<b>3M - High dose main</b>									
20	3485 7.1	ND	NA	ND	NA	28.97	4.07	NA	NA
14	3486 7.1	ND	NA	ND	NA	26.49	0.11	NA	NA
16	3531 7.1	ND	NA	ND	NA	26.46	0.08	NA	NA
<b>3F - High dose main</b>									
33	3483 7.1	ND	NA	ND	NA	26.01	0.49	NA	NA
32	3490 7.1	ND	NA	ND	NA	26.05	0.15	NA	NA
31	3379 7.1	ND	NA	ND	NA	25.57	0.13	NA	NA

<b>Iliac lymph node</b>		<b>N (Ct - Av.)</b>	<b>N (Ct - STD)</b>	<b>S (Ct - Av.)</b>	<b>S (Ct - STD)</b>	<b>HPRT (Ct - Av.)</b>	<b>HPRT (Ct - STD)</b>	<b>Vaccine amount (PFU) - N</b>	<b>Vaccine amount (PFU) - S</b>
<b>#</b>	<b>Sample</b>								
1M - Control main									
<b>1</b>	<b>3447 10.1</b>	ND	NA	ND	NA	27.24	0.04	<b>NA</b>	<b>NA</b>
<b>5</b>	<b>3473 10.1</b>	ND	NA	ND	NA	27.04	0.04	<b>NA</b>	<b>NA</b>
<b>9</b>	<b>3511 10.1</b>	ND	NA	ND	NA	26.68	1.67	<b>NA</b>	<b>NA</b>
1F - Control main									
<b>4</b>	<b>3470 10.1</b>	ND	NA	ND	NA	26.17	0.01	<b>NA</b>	<b>NA</b>
<b>12</b>	<b>3395 10.1</b>	ND	NA	ND	NA	27.54	0.16	<b>NA</b>	<b>NA</b>
<b>8</b>	<b>3489 10.1</b>	ND	NA	ND	NA	26.76	0.08	<b>NA</b>	<b>NA</b>
3M - High dose main									
<b>30</b>	<b>3485 10.1</b>	28.37	0.01	33.16	0.04	26.21	0.08	<b>166.48</b>	<b>115.27</b>
<b>29</b>	<b>3486 10.1</b>	35.41	1.11	40.28	1.08	26.99	0.04	<b>&lt;10</b>	<b>NA</b>
<b>28</b>	<b>3531 10.1</b>	31.53	0.35	37.17	0.45	27.01	0.06	<b>30.95</b>	<b>11.73</b>
3F - High dose main									
<b>27</b>	<b>3483 10.1</b>	30.35	0.01	35.92	0.28	26.91	0.21	<b>67.08</b>	<b>26.57</b>
<b>26</b>	<b>3490 10.1</b>	30.63	0.38	35.95	0.52	27.17	0.04	<b>66.14</b>	<b>31.40</b>
<b>25</b>	<b>3379 10.1</b>	28.10	0.49	33.58	0.57	26.32	0.10	<b>219.84</b>	<b>92.81</b>

<b>Brain</b>		N (Ct - Av.)	N (Ct - STD)	S (Ct - Av.)	S (Ct - STD)	HPRT (Ct - Av.)	HPRT (Ct - STD)	Vaccine amount (PFU) - N	Vaccine amount (PFU) - S
<b>#</b>	<b>Sample</b>								
<b>1M - Control main</b>									
<b>6</b>	<b>3447 1.1</b>	ND	NA	ND	NA	24.66	0.22	NA	NA
<b>5</b>	<b>3473 1.1</b>	ND	NA	ND	NA	24.35	0.01	NA	NA
<b>12</b>	<b>3511 1.1</b>	ND	NA	ND	NA	24.72	0.45	NA	NA
<b>1F - Control main</b>									
<b>11</b>	<b>3470 1.1</b>	ND	NA	ND	NA	24.94	0.04	NA	NA
<b>10</b>	<b>3395 1.1</b>	ND	NA	ND	NA	24.43	0.28	NA	NA
<b>9</b>	<b>3489 1.1</b>	ND	NA	ND	NA	24.83	0.05	NA	NA
<b>3M - High dose main</b>									
<b>4</b>	<b>3485 1.1</b>	ND	NA	ND	NA	24.73	0.43	NA	NA
<b>3</b>	<b>3486 1.1</b>	ND	NA	ND	NA	24.23	0.06	NA	NA
<b>2</b>	<b>3531 1.1</b>	ND	NA	ND	NA	24.94	0.13	NA	NA
<b>3F - High dose main</b>									
<b>1</b>	<b>3483 1.1</b>	ND	NA	ND	NA	24.76	0.08	NA	NA
<b>8</b>	<b>3490 1.1</b>	ND	NA	ND	NA	24.72	0.11	NA	NA
<b>7</b>	<b>3379 1.1</b>	ND	NA	ND	NA	24.18	0.21	NA	NA

<b>Heart</b>		N (Ct - Av.)	N (Ct - STD)	S (Ct - Av.)	S (Ct - STD)	HPRT (Ct - Av.)	HPRT (Ct - STD)	Vaccine amount (PFU) - N	Vaccine amount (PFU) - S
#	Sample								
<b>1M - Control main</b>									
13	3447 3.1	ND	NA	ND	NA	26.49	0.18	NA	NA
14	3473 3.1	ND	NA	ND	NA	26.83	0.05	NA	NA
15	3511 3.1	ND	NA	ND	NA	26.19	0.01	NA	NA
<b>1F - Control main</b>									
16	3470 3.1	ND	NA	ND	NA	26.55	0.20	NA	NA
17	3395 3.1	ND	NA	ND	NA	27.43	0.28	NA	NA
18	3489 3.1	ND	NA	ND	NA	27.26	0.04	NA	NA
<b>3M - High dose main</b>									
19	3485 3.1	ND	NA	ND	NA	27.14	0.37	NA	NA
20	3486 3.1	ND	NA	ND	NA	26.51	0.06	NA	NA
21	3531 3.1	ND	NA	ND	NA	26.68	0.03	NA	NA
<b>3F - High dose main</b>									
22	3483 3.1	ND	NA	ND	NA	27.05	0.04	NA	NA
23	3490 3.1	ND	NA	ND	NA	27.71	1.04	NA	NA
24	3379 3.1	ND	NA	ND	NA	30.59	0.42	NA	NA

<b>Kidney</b>		N (Ct - Av.)	N (Ct - STD)	S (Ct - Av.)	S (Ct - STD)	HPRT (Ct - Av.)	HPRT (Ct - STD)	Vaccine amount (PFU) - N	Vaccine amount (PFU) - S
<b>#</b>	<b>Sample</b>								
<b>1M - Control main</b>									
<b>2</b>	<b>3447 6.1</b>	ND	NA	ND	NA	28.59	0.31	NA	NA
<b>5</b>	<b>3473 6.1</b>	ND	NA	ND	NA	29.05	0.40	NA	NA
<b>3</b>	<b>3511 6.1</b>	ND	NA	ND	NA	29.88	0.17	NA	NA
<b>1F - Control main</b>									
<b>4</b>	<b>3470 6.1</b>	ND	NA	ND	NA	30.08	0.20	NA	NA
<b>1</b>	<b>3395 6.1</b>	ND	NA	ND	NA	28.96	0.18	NA	NA
<b>6</b>	<b>3489 6.1</b>	ND	NA	ND	NA	28.19	0.36	NA	NA
<b>3M - High dose main</b>									
<b>7</b>	<b>3485 6.1</b>	ND	NA	ND	NA	28.39	0.11	NA	NA
<b>9</b>	<b>3486 6.1</b>	ND	NA	ND	NA	29.36	0.33	NA	NA
<b>10</b>	<b>3531 6.1</b>	ND	NA	ND	NA	28.29	0.08	NA	NA
<b>3F - High dose main</b>									
<b>11</b>	<b>3483 6.1</b>	ND	NA	ND	NA	27.77	0.18	NA	NA
<b>12</b>	<b>3490 6.1</b>	ND	NA	ND	NA	30.09	0.95	NA	NA
<b>8</b>	<b>3379 6.1</b>	ND	NA	ND	NA	28.54	0.01	NA	NA

<b>Liver</b>		N (Ct - Av.)	N (Ct - STD)	S (Ct - Av.)	S (Ct - STD)	HPRT (Ct - Av.)	HPRT (Ct - STD)	Vaccine amount (PFU) - N	Vaccine amount (PFU) - S
<b>#</b>	<b>Sample</b>								
<b>1M - Control main</b>									
<b>13</b>	<b>3447 9.1</b>	ND	NA	ND	NA	27.80	0.43	NA	NA
<b>14</b>	<b>3473 9.1</b>	ND	NA	ND	NA	28.06	0.83	NA	NA
<b>15</b>	<b>3511 9.1</b>	ND	NA	ND	NA	27.68	0.69	NA	NA
<b>1F - Control main</b>									
<b>16</b>	<b>3470 9.1</b>	ND	NA	ND	NA	28.01	0.08	NA	NA
<b>17</b>	<b>3395 9.1</b>	ND	NA	ND	NA	29.03	0.01	NA	NA
<b>18</b>	<b>3489 9.1</b>	ND	NA	ND	NA	28.73	0.11	NA	NA
<b>3M - High dose main</b>									
<b>19</b>	<b>3485 9.1</b>	ND	NA	ND	NA	28.36	NA	NA	NA
<b>20</b>	<b>3486 9.1</b>	ND	NA	ND	NA	28.51	0.06	NA	NA
<b>21</b>	<b>3531 9.1</b>	ND	NA	ND	NA	27.70	0.54	NA	NA
<b>3F - High dose main</b>									
<b>22</b>	<b>3483 9.1</b>	ND	NA	ND	NA	28.98	0.14	NA	NA
<b>23</b>	<b>3490 9.1</b>	ND	NA	ND	NA	28.20	0.02	NA	NA
<b>24</b>	<b>3379 9.1</b>	ND	NA	ND	NA	28.14	0.00	NA	NA



<b>Thymus</b>		N (Ct - Av.)	N (Ct - STD)	S (Ct - Av.)	S (Ct - STD)	HPRT (Ct - Av.)	HPRT (Ct - STD)	Vaccine amount (PFU) - N	Vaccine amount (PFU) - S
<b>#</b>	<b>Sample</b>								
<b>1M - Control main</b>									
<b>1</b>	<b>3447 2.1</b>	ND	NA	ND	NA	27.12	0.07	NA	NA
<b>2</b>	<b>3473 2.1</b>	ND	NA	ND	NA	27.46	0.35	NA	NA
<b>3</b>	<b>3511 2.1</b>	ND	NA	ND	NA	27.47	0.04	NA	NA
<b>1F - Control main</b>									
<b>4</b>	<b>3470 2.1</b>	ND	NA	ND	NA	27.60	0.03	NA	NA
<b>5</b>	<b>3395 2.1</b>	ND	NA	ND	NA	27.27	0.05	NA	NA
<b>6</b>	<b>3489 2.1</b>	ND	NA	ND	NA	27.14	0.13	NA	NA
<b>3M - High dose main</b>									
<b>7</b>	<b>3485 2.1</b>	ND	NA	ND	NA	27.36	0.04	NA	NA
<b>8</b>	<b>3486 2.1</b>	ND	NA	ND	NA	27.97	0.64	NA	NA
<b>9</b>	<b>3531 2.1</b>	ND	NA	ND	NA	27.68	0.80	NA	NA
<b>3F - High dose main</b>									
<b>10</b>	<b>3483 2.1</b>	ND	NA	ND	NA	26.55	0.73	NA	NA
<b>11*</b>	<b>3490 2.1</b>	ND	NA	ND	NA	ND	NA	NA	NA
<b>12</b>	<b>3379 2.1</b>	ND	NA	ND	NA	27.77	0.62	NA	NA

Testis/Ovary		N (Ct - Av.)	N (Ct - STD)	S (Ct - Av.)	S (Ct - STD)	HPRT (Ct - Av.)	HPRT (Ct - STD)	Vaccine amount (PFU) - N	Vaccine amount (PFU) - S
#	Sample								
<b>1M - Control main</b>									
13	3447 8.1	ND	NA	ND	NA	26.18	0.70	NA	NA
14	3473 8.1	ND	NA	ND	NA	26.47	0.65	NA	NA
15	3511 8.1	ND	NA	ND	NA	26.42	0.62	NA	NA
<b>1F - Control main</b>									
16	3470 8.1	ND	NA	ND	NA	27.84	0.59	NA	NA
17	3395 8.1	ND	NA	ND	NA	28.03	0.04	NA	NA
18	3489 8.1	ND	NA	ND	NA	28.11	0.03	NA	NA
<b>3M - High dose main</b>									
19	3485 8.1	ND	NA	ND	NA	26.08	0.13	NA	NA
20	3486 8.1	ND	NA	ND	NA	26.40	0.08	NA	NA
21	3531 8.1	ND	NA	ND	NA	25.99	0.07	NA	NA
<b>3F - High dose main</b>									
22	3483 8.1	ND	NA	ND	NA	27.43	0.39	NA	NA
23	3490 8.1	ND	NA	ND	NA	27.53	0.10	NA	NA
24	3379 8.1	ND	NA	ND	NA	27.84	0.19	NA	NA

<b>Bone marrow from the femur</b>		<b>N (Ct - Av.)</b>	<b>N (Ct - STD)</b>	<b>S (Ct - Av.)</b>	<b>S (Ct - STD)</b>	<b>HPRT (Ct - Av.)</b>	<b>HPRT (Ct - STD)</b>	<b>Vaccine amount (PFU) - N</b>	<b>Vaccine amount (PFU) - S</b>
<b>#</b>	<b>Sample</b>								
1M - Control main									
<b>25</b>	<b>3447 12.1</b>	ND	NA	ND	NA	30.07	0.01	<b>NA</b>	<b>NA</b>
<b>26</b>	<b>3473 12.1</b>	ND	NA	ND	NA	28.93	0.22	<b>NA</b>	<b>NA</b>
<b>27</b>	<b>3511 12.1</b>	ND	NA	ND	NA	28.93	0.16	<b>NA</b>	<b>NA</b>
1F - Control main									
<b>28</b>	<b>3470 12.1</b>	ND	NA	ND	NA	29.96	0.18	<b>NA</b>	<b>NA</b>
<b>29</b>	<b>3395 12.1</b>	ND	NA	ND	NA	28.87	0.59	<b>NA</b>	<b>NA</b>
<b>30</b>	<b>3489 12.1</b>	ND	NA	ND	NA	29.48	0.06	<b>NA</b>	<b>NA</b>
3M - High dose main									
<b>31</b>	<b>3485 12.1</b>	ND	NA	ND	NA	29.29	0.13	<b>NA</b>	<b>NA</b>
<b>32</b>	<b>3486 12.1</b>	ND	NA	ND	NA	29.68	0.01	<b>NA</b>	<b>NA</b>
<b>33</b>	<b>3531 12.1</b>	ND	NA	ND	NA	31.47	0.83	<b>NA</b>	<b>NA</b>
3F - High dose main									
<b>34</b>	<b>3483 12.1</b>	ND	NA	ND	NA	29.15	0.02	<b>NA</b>	<b>NA</b>
<b>35</b>	<b>3490 12.1</b>	ND	NA	ND	NA	28.46	0.12	<b>NA</b>	<b>NA</b>
<b>36</b>	<b>3379 12.1</b>	ND	NA	ND	NA	30.36	0.05	<b>NA</b>	<b>NA</b>

Iliac lymph node		N (Ct - Av.)	N (Ct - STD)	S (Ct - Av.)	S (Ct - STD)	HPRT (Ct - Av.)	HPRT (Ct - STD)	Vaccine amount (PFU) - N	Vaccine amount (PFU) - S
#	Sample								
<b>1M - Control recovery</b>									
<b>1</b>	<b>3453.10.1</b>	ND	NA	ND	NA	26.92	0.40	<b>NA</b>	<b>NA</b>
<b>5</b>	<b>3464.10.1</b>	ND	NA	ND	NA	26.24	0.47	<b>NA</b>	<b>NA</b>
<b>9</b>	<b>3498.10.1</b>	ND	NA	ND	NA	26.05	0.01	<b>NA</b>	<b>NA</b>
<b>1F - Control recovery</b>									
<b>2</b>	<b>3418.10.1</b>	ND	NA	ND	NA	26.55	0.63	<b>NA</b>	<b>NA</b>
<b>6</b>	<b>3400.10.1</b>	ND	NA	ND	NA	26.36	0.48	<b>NA</b>	<b>NA</b>
<b>10</b>	<b>3414.10.1</b>	ND	NA	ND	NA	26.80	0.15	<b>NA</b>	<b>NA</b>
<b>3M - High dose recovery</b>									
<b>3</b>	<b>3446.10.1</b>	34.60	0.18	41.57	0.49	25.21	0.26	<b>&lt;10</b>	<b>&lt;10</b>
<b>7</b>	<b>3426.10.1</b>	ND	NA	ND	NA	26.29	0.37	<b>NA</b>	<b>NA</b>
<b>11</b>	<b>3519.10.1</b>	28.44	0.02	34.59	0.33	25.30	0.02	<b>83.08</b>	<b>21.78</b>
<b>3F - High dose recovery</b>									
<b>4</b>	<b>3406.10.1</b>	33.14	0.54	39.47	0.22	25.13	0.40	<b>&lt;10</b>	<b>&lt;10</b>
<b>8</b>	<b>3408.10.1</b>	30.49	0.06	36.64	0.45	25.29	0.57	<b>19.06</b>	<b>&lt;10</b>
<b>12</b>	<b>3433.10.1</b>	33.27	1.15	40.16	2.17	26.23	0.01	<b>&lt;10</b>	<b>&lt;10</b>

The Ct is a relative measure of the concentration of target in the PCR reaction (low Cp = high concentration); Av = Average; NA = Not Applicable; ND = Not Detected; STD = Standard Deviation; Average and Standard Deviation values of duplicates performed;

\* HPRT not detected; \*\* Low RNA extraction yield; \*\*\* 35.64 for one replicate and not detected in the other replicate in 1st run; 34.22 for one replicate and not detected in the other replicate in 2nd run.

For "S" - Samples not detected for both qPCR replicates, and samples with Ct > 39.0 in one replicate and not detected in the second replicate are marked as ND.

For "N" - Samples not detected for both qPCR replicates, and samples with Ct > 35.9 in one replicate and not detected in the second replicate are marked as ND.

Vaccine amount calculations were performed for samples with average N Ct < 36 and/or average S Ct < 40, using the following equations:

- Equation for N:  $\text{Log(PFU)} = ((\text{Ct-N minus Ct-HPRT}) - 9.34)/(-3.23)$
- Equation for S:  $\text{Log(PFU)} = ((\text{Ct-S minus Ct-HPRT}) - 13.63)/(-3.24)$